# EDGAR Filing Document

**Accession Number:** 0001854270
**File Stem:** 0001854270-23-000024
**Filing Date:** 2023-2
**Character Count:** 17239
**Document Hash:** c281fb12f23274358303c7623eb9ffc4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001854270-23-000024.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0001854270-23-000024

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230215

**EFFECTIVENESS DATE**: 20230216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Senti Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001854270
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 862437900
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269816
- **FILM NUMBER:** 23636685

**BUSINESS ADDRESS:**
- **STREET 1:** 2 CORPORATE DRIVE, FIRST FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 382-3281

**MAIL ADDRESS:**
- **STREET 1:** 2 CORPORATE DRIVE, FIRST FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Senti Biosciences, Inc.\
- **DATE OF NAME CHANGE:** 20220615

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Dynamics Special Purpose Corp.
- **DATE OF NAME CHANGE:** 20210331

**As filed with the Securities and Exchange Commission on February 15, 2023**

**Registration No. 333-[ ]**

_____________________________________________________________________________

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**SENTI BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware<br>(State or other jurisdiction of incorporation)** | **2 Corporate Drive, First Floor<br>South San Francisco, CA 94080<br>Telephone: (650) 382-3281** | **86-2437900<br>(IRS Employer Identification No.)** |

---

**Senti Biosciences, Inc. 2022 Equity Incentive Plan** 

**Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan**

(Full title of the plans)

_____________________________________________________________________________

**Timothy Lu, M.D., Ph.D**

**Chief Executive Officer**

**Senti Biosciences, Inc.**

**2 Corporate Drive, First Floor**

**South San Francisco, CA 94080**

**Telephone: (650) 382-3281**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

_____________________________________________________________________________

***Copies to:***

**Jocelyn M. Arel**

**Maggie Wong**

**Michael R. Patrone**

**Goodwin Procter LLP**

**620 Eighth Avenue**

**New York, NY 10018**

**(212) 813-8800** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

_____________________________________________________________________________

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by Senti Biosciences, Inc. (the "Company") to register 2,208,401 additional shares of common stock, par value $0.0001 per share, reserved and available for issuance under the Senti Biosciences, Inc. 2022 Equity Incentive Plan (the "2022 Equity Incentive Plan") and also to register 441,680 additional shares of common stock, par value $0.0001 per share, reserved and available for issuance under the Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan (the "2022 Employee Stock Purchase Plan").

Pursuant to General Instruction E for Form S-8 regarding Registration of Additional Securities, the contents of the Registration Statement on Form S-8 File No. 333-266958 filed with the Securities and Exchange Commission on August 18, 2022 is hereby incorporated by reference in this Registration Statement to the extent not replaced hereby.

**PART II**

**Item 8. Exhibits.**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 4.1 | <u>[Second Amended and Restated Certificate of Incorporation of the registrant (incorporated by reference](https://www.sec.gov/Archives/edgar/data/0001854270/000119312522174498/d360749dex31.htm)[from](https://www.sec.gov/Archives/edgar/data/0001854270/000119312522174498/d360749dex31.htm)[Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on June 15, 2022)](https://www.sec.gov/Archives/edgar/data/0001854270/000119312522174498/d360749dex31.htm)</u>. |
| 4.2 | <u>[Amended and Restated Bylaws of the registrant (incorporated by reference](https://www.sec.gov/Archives/edgar/data/0001854270/000119312522174498/d360749dex32.htm)[from](https://www.sec.gov/Archives/edgar/data/0001854270/000119312522174498/d360749dex32.htm)[Exhibit 3.2 to the current report on Form 8-K filed with the Commission on June 15, 202](https://www.sec.gov/Archives/edgar/data/0001854270/000119312522174498/d360749dex32.htm)[2](https://www.sec.gov/Archives/edgar/data/0001854270/000119312522174498/d360749dex32.htm)[)](https://www.sec.gov/Archives/edgar/data/0001854270/000119312522174498/d360749dex32.htm)</u>. |
| 5.1\* | <u>[Opinion of Goodwin Procter LLP.](a20230215s8ex51.htm)</u> |
| 23.1\* | <u>[Consent of Marcum LLP.](a20230215s8ex231.htm)</u> |
| 23.2\* | <u>[Consent of KPMG LLP.](a20230215s8ex232.htm)</u> |
| 23.3\* | <u>[Consent of Goodwin Procter LLP (included in Exhibit 5.1).](a20230215s8ex51.htm)</u> |
| 24.1\* | <u>[Power of Attorney (included on signature page of this registration statement).](#i301301d34cce44b6b882f7ce8e5b6ad6_123)</u> |
| 99.1 | <u>[Senti Biosciences, Inc. 2022 Equity Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.3 to the quarterly report on Form 10-Q, filed with the Commission on August 15, 2022).](https://www.sec.gov/Archives/edgar/data/0001854270/000185427022000019/a6302210qex103.htm)</u> |
| 99.2 | <u>[Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q, filed with the Commission on August 15, 2022).](https://www.sec.gov/Archives/edgar/data/0001854270/000185427022000019/a6302210qex104.htm)</u> |
| 107\* | <u>[Filing Fee Table](a20230215s8ex107.htm)</u> |

---

________________

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, CA on the 15 day of February, 2023.

---

| | |
|:---|:---|
| **SENTI BIOSCIENCES, INC.** | **SENTI BIOSCIENCES, INC.** |
| By: | /s/ Timothy Lu |
| Name: | Timothy Lu, M.D., Ph.D. |
| Title: | Chief Executive Officer and President (Principal Executive Officer) |

---

------

**POWER OF ATTORNEY AND SIGNATURES**

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints each of Timothy Lu and Deborah Knobelman as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following person in the capacities and on the date indicated below.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Timothy Lu | Chief Executive Officer, President and Director<br>(Principal Executive Officer) | February 15, 2023 |
| Timothy Lu, M.D., Ph.D. | Chief Executive Officer, President and Director<br>(Principal Executive Officer) | February 15, 2023 |
| /s/ Deborah Knobelman | Chief Financial Officer<br>(Principal Financial Officer and<br>Principal Accounting Officer) | February 15, 2023 |
| Deborah Knobelman, Ph.D. | Chief Financial Officer<br>(Principal Financial Officer and<br>Principal Accounting Officer) | February 15, 2023 |
| /s/ Susan Berland | Director | February 15, 2023 |
| Susan Berland | Director | February 15, 2023 |
| /s/ Brenda Cooperstone | Director | February 15, 2023 |
| Brenda Cooperstone, M.D. | Director | February 15, 2023 |
| /s/ Edward Mathers | Director | February 15, 2023 |
| Edward Mathers | Director | February 15, 2023 |
| /s/ James J. Collins | Director | February 15, 2023 |
| James J. (Jim) Collins, Ph.D. | Director | February 15, 2023 |
| /s/ Omid Farokhzad | Director | February 15, 2023 |
| Omid Farokhzad, M.D. | Director | February 15, 2023 |
| /s/ David Epstein | Director | February 15, 2023 |
| David Epstein | Director | February 15, 2023 |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**S-8**

(Form Type)

**Senti Biosciences, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Unit** | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common stock, par value $0.0001 per share, under 2022 Employee Stock Purchase Plan | Rule 457(c) and Rule 457(h) | 441680 | <sup>(3)</sup> | $1.72 | <sup>(2)</sup> | $759689.60 | 0.0001102 | $83.72 |
| Equity | Common stock, par value $0.0001 per share, under 2022 Equity Incentive Plan | Rule 457(c) and Rule 457(h) | 2208401 | <sup>(4)</sup> | $1.72 | <sup>(2)</sup> | $3798449.72 | 0.0001102 | $418.59 |
| **Total Offering Amounts** | **Total Offering Amounts** |  | 2650081 |  |  |  | $4558139.32 |  | $502.31 |
| **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  |  |  | $— |
| **Net Fees Due** | **Net Fees Due** |  |  |  |  |  |  |  | $502.31 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers an indeterminate number of additional shares that may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2) Estimated pursuant to Rules 457(c) and 457(h) under the Securities Act, solely for the purposes of calculating the registration fee and based on the average of the high and low prices of the registrant's common stock as reported on the Nasdaq Global Market on February 8, 2023, which date is within five business days prior to the filing of this registration statement.

(3) Represents 441,680 shares of the registrant's common stock currently reserved for future issuance under the 2022 Employee Stock Purchase Plan. The 2022 Employee Stock Purchase Plan contains an evergreen provision under which the number of authorized shares cumulatively increases, on January 1 of each year, in an amount equal to the lesser of (i) one percent (1%) of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) 1,000,000 shares of Company common stock. Unless the 2022 Employee Stock Purchase Plan is earlier amended or terminated, this evergreen provision increases shares over a ten year period, from January 1, 2023 through January 1, 2032.

(4) Represents 2,208,401 shares of the Company's common stock reserved for future issuance under the 2022 Equity Incentive Plan. The 2022 Equity Incentive Plan contains an evergreen provision under which the number of authorized shares cumulatively increases, on January 1 of each year, by 5% of the outstanding number of shares of common stock of the Company on the immediately preceding December 31, or such lesser number of shares as approved by the Board of Directors, based on the recommendations of the Compensation Committee of the Board of Directors. Unless the 2022 Equity Incentive Plan is earlier amended or terminated, this evergreen provision increases shares over a ten year period, from January 1, 2023 through January 1, 2032.

## Exhibit 5.1

**Exhibit 5.1**

February 15, 2023

Senti Biosciences, Inc.

2 Corporate Drive, First Floor

South San Francisco, CA 94080

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 2,650,081 shares (the "Shares") of common stock, $0.0001 par value per share ("Common Stock"), of Senti Biosciences, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2022 Equity Incentive Plan, and 2022 Employee Stock Purchase Plan (collectively, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 Business Lawyer 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Goodwin Procter LLP

Goodwin Procter LLP

## Exhibit 23.1

**Exhibit 23.1**

<u>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT</u>

We consent to the incorporation by reference in this Registration Statement of Senti Biosciences, Inc. (formerly Dynamics Special Purpose Corp.) on Form S-8 of our report dated March 7, 2022 (which includes an explanatory paragraph as to the Company's ability to continue as a going concern), with respect to our audit of the consolidated financial statements of Senti Biosciences, Inc. (formerly Dynamics Special Purpose Corp.) as of December 31, 2021 and for the period from March 1, 2021 (inception) through December 31, 2021, which report appears in the Prospectus, which is incorporated by reference in this Registration Statement. We were dismissed as auditors on June 8, 2022 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements appearing in such Prospectus for the periods after the date of our dismissal. We also consent to the reference to our Firm under the heading "Experts" in such Prospectus.

/s/ Marcum LLP

Marcum LLP

Houston, Texas

February 15, 2023

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated April 1, 2022, with respect to the consolidated financial statements of Senti Biosciences, Inc. and its subsidiaries, incorporated herein by reference.

/s/ KPMG LLP

San Francisco, California

February 15, 2023

<br>